A mechanistic understanding of human magnetoreception validates the phenomenon of electromagnetic hypersensitivity (EHS).

Background: Human electromagnetic hypersensitivity (EHS) or electrosensitivity (ES) symptoms in response to anthropogenic electromagnetic fields (EMFs) at levels below current international safety standards are generally considered to be nocebo effects by conventional medical science. In the wider field of magnetoreception in biology, our understanding of mechanisms and processes of magnetic field (MF) interactions is more advanced.

Methods: We consulted a range of publication databases to identify the key advances in understanding of magnetoreception across the wide animal kingdom of life.

Hypotension duration and vasopressor requirements following intrathecal oxytocin for Total hip arthroplasty: Secondary analysis of a randomized controlled trial.

Introduction: A recent publication investigating intrathecal oxytocin, 100 μg, administered immediately prior to a spinal anesthetic in patients undergoing primary total hip arthroplasty surgery demonstrated a reduction in disability for 3-weeks, increased walking distance at 8-weeks, and earlier opioid cessation. This secondary analysis study was undertaken to assess the acute cardiovascular safety and analgesic efficacy of intrathecal oxytocin in this study population.

Methods: 90 patients were included in the analysis (44 randomized to spinal oxytocin and 46 to placebo [saline]).

Evaluating residual anti-Xa levels following discontinuation of treatment-dose enoxaparin in patients presenting for elective surgery: a prospective observational trial.

Introduction: Prior studies have demonstrated that patients presenting for elective surgery may have higher-than-expected residual anti-Xa level activity at or beyond 24 hours following their last treatment dose of enoxaparin. Given that 24 hours of abstinence is currently recommended by both European and American societies before the performance of neuraxial or deep anesthetic/analgesic procedures, determining the actual timeframe at which residual anti-Xa level activity reliably falls below 0.2 IU/mL, the lower limit of the target range for thromboprophylaxis, is critical.